GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VBI Vaccines Inc (NAS:VBIV) » Definitions » Median PS Value

VBI Vaccines (VBI Vaccines) Median PS Value : $0.00 (As of May. 12, 2024)


View and export this data going back to 2016. Start your Free Trial

What is VBI Vaccines Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. VBI Vaccines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.489. VBI Vaccines's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-05-12), VBI Vaccines's share price is $0.62. VBI Vaccines's Median PS Value is $0.00. Therefore, VBI Vaccines's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for VBI Vaccines's Median PS Value or its related term are showing as below:

VBIV's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.7
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

VBI Vaccines Median PS Value Historical Data

The historical data trend for VBI Vaccines's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VBI Vaccines Median PS Value Chart

VBI Vaccines Annual Data
Trend Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

VBI Vaccines Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of VBI Vaccines's Median PS Value

For the Biotechnology subindustry, VBI Vaccines's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VBI Vaccines's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VBI Vaccines's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where VBI Vaccines's Price-to-Median-PS-Value falls into.



VBI Vaccines Median PS Value Calculation

VBI Vaccines's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.489*0
=0.00

10-Year Median PS Ratio is 0.
VBI Vaccines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.489.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VBI Vaccines  (NAS:VBIV) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

VBI Vaccines's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.62/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VBI Vaccines Median PS Value Related Terms

Thank you for viewing the detailed overview of VBI Vaccines's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


VBI Vaccines (VBI Vaccines) Business Description

Traded in Other Exchanges
Address
160 Second Street, Floor 3, Cambridge, MA, USA, 02142
VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Executives
Steven Gillis director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Vaughn B Himes director C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Robert Dillman officer: Chief Commercial Officer C/O VBI VACCINES INC., 160 SECOND STREET, FLOOR 3, CAMBRIDGE MA 02142
Nell Beattie officer: Director, Corp Development/IR 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Linda Bain director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Damian Braga director 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Francisco Diaz-mitoma officer: Chief Medical Officer 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Christopher Mcnulty officer: CFO and Head of BD C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeff Baxter director, officer: President and CEO C/O VBI VACCINES INC.,, 222 THIRD STREET, STE 2241, CAMBRIDGE MA 02142
Joanne Cordeiro director 171 SWANTON STREET, UNIT 48, WINCHESTER MA 01890
Blaine H. Mckee director C/O HART, 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
Tomer Kariv director C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

VBI Vaccines (VBI Vaccines) Headlines

From GuruFocus